Company intelligence / Profile preview
Inhibrx Biosciences
La Jolla, California, United States
- Ownership
- Private
- Employees
- ~161
- Development stage
- Other
01
Overview
Ozekibart (INBRX-109) is in a registration-enabling Phase 2 trial for metastatic/unresectable conventional chondrosarcoma and has received Fast Track and Orphan Drug Designations from the FDA; early data also suggest benefit in Ewing sarcoma and colorectal cancer. INBRX-106, a hexavalent OX40 agonist, showed promising clinical activity in Phase 1/2 trials and is advancing into randomized Phase 2/3 studies.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodySingle domain antibodyRecombinant proteinEngineered cytokineMulti-specific moleculeFc-fusion protein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Inhibrx Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhibrx Biosciences.